Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer

被引：0

作者：

Earashi, M. ^{[1
]}

Matsui, K. ^{[2
]}

Maeda, K. ^{[2
]}

Fukushima, W. ^{[3
]}

Shimada, K. ^{[4
]}

Shimizu, T. ^{[5
]}

Nozaki, Z. ^{[6
]}

Tanada, Y. ^{[6
]}

Oyama, K. ^{[7
]}

Nagata, T. ^{[8
]}

Tsuneda, A. ^{[9
]}

Yoshikawa, A. ^{[10
]}

Yoshida, T. ^{[11
]}

Kiyohara, K. ^{[12
]}

Iwata, K. ^{[13
]}

Ii, T. ^{[14
]}

机构：

[1] Yatsuo Gen Hosp, Dept Breast Suegery, Toyama, Japan

[2] Toyama Prefectural Cent Hosp, Depertment Surg, Toyama, Japan

[3] Takaoka City Hosp, Derartment Surg, Takaoka, Toyama, Japan

[4] Imizu Municipal Hosp, Dept Surg, Imizu, Toyama, Japan

[5] Saiseikai Toyama Hosp, Dept Surg, Toyama, Japan

[6] Toyama Red Cross Hosp, Dept Surg, Toyama, Japan

[7] Kouseiren Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan

[8] Toyama Univ Hosp, Dept Surg, Toyama, Japan

[9] Toyama Rosai Hosp, Dept Surg, Uozu, Toyama, Japan

[10] Toyama City Hosp, Dept Surg, Toyama, Japan

[11] Saiseikai Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan

[12] Tonami Gen Hosp, Dept Surg, Tonami, Toyama, Japan

[13] Kurobe City Hosp, Dept Surg, Kurobe, Japan

[14] Kouseiren Namerikawa Hosp, Dept Surg, Namerikawa, Japan

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

110P

引用

页码：32 / 32

页数：1

共 50 条

[31] Eribulin in the treatment of patients with advanced breast cancer
Lacko, Aleksandra
ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (01): : 10 - 14
[32] Pneumonia induced by eribulin mesylate in a patient with recurrent breast cancer
Hiroo Ishida
Tetsuya Homma
Koko Ishida
Tomohide Sugiyama
Sojiro Kusumoto
Takao Shirai
Masanao Nakashima
Tsukasa Ohnishi
Takashi Hirose
International Cancer Conference Journal, 2013, 2 (3) : 135 - 138
[33] The safety of eribulin for the treatment of metastatic breast cancer
Manuel Perez-Garcia, Jose
Cortes, Javier
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (05) : 347 - 355
[34] Bevacizumab in the treatment of breast cancer
Sirohi, Bhawna
Smith, Katy
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (10) : 1559 - 1568
[35] Bevacizumab in the treatment of breast cancer
Koutras, Angelos K.
Fountzilas, George
Makatsoris, Thomas
Peroukides, Stavros
Kalofonos, Haralabos P.
CANCER TREATMENT REVIEWS, 2010, 36 (01) : 75 - 82
[36] An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry
Pouwels, Xavier G. L., V
Ramaekers, Bram L. T.
Geurts, Sandra M. E.
Erdkamp, Frans
Vriens, Birgit E. P. J.
Aaldering, Kirsten N. A.
van de Wouw, Agnes J.
Dercksen, M. W.
Smilde, Tineke J.
Peters, Natascha A. J. B.
van Riel, J. M. G. H.
Pepels, Manon J.
Heijnen-Mommers, Jose
Tjan-Heijnen, Vivianne C. G.
de Boer, Maaike
Joore, Manuela A.
ACTA ONCOLOGICA, 2020, 59 (09) : 1123 - 1130
[37] Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience
Sanganalmath, P.
Purohit, K.
Winter, M.
Horsman, J.
Ramakrishnan, S.
Hatton, M.
Lee, C.
Dunn, K.
Din, O.
Coleman, R.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S181 - S182
[38] Eribulin in the treatment of breast cancer: an important weapon in the treatment algorithm
Zamagni, Claudio
FUTURE ONCOLOGY, 2017, 13 (11) : 1 - 3
[39] Efficacy and safety of eribulin in real life in the treatment of metastasic breast cancer in a Spanish general center
Ruiz, Ignacio Patier
Peiro, Juan Francisco Marquez
REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2022, 35 (04): : 221 - 227
[40] Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting
Dranitsaris, George
Tripathy, Debu
Beegle, Nancy L.
Kalberer, Traci L.
Cox, John David
Faria, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)

← 1 2 3 4 5 →